What is Castle Biosciences's net change in loans and leases?

Castle Biosciences (CSTL) reported net change in loans and leases of $528.5K in Q4 2025.

What does net change in loans and leases mean?

Net change in bank loan portfolio from originations, paydowns, charge-offs, and sales.

Castle Biosciences CSTL Net change in loans and leases

Net change in loans and leases at other companies

CNB FinancialCCNE

-$63.25M-5,128%

BSR

Sierra BancorpBSRR

-$79.76M-217%

First Business Financial ServicesFBIZ

$127.83M+71.2%

ChoiceOne FinancialCOFS

-$41.37M-724%

Coastal FinancialCCB

-$9K—

Mercantile Bank CorporationMBWM

-$5.71M-116%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireFinanceReceivables.

The official record: Castle Biosciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's net change in loans and leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's net change in loans and leases?: Castle Biosciences (CSTL) reported net change in loans and leases of $528.5K in Q4 2025.
What does net change in loans and leases mean?: Net change in bank loan portfolio from originations, paydowns, charge-offs, and sales.